首页> 美国卫生研究院文献>Clinical Neuropathology >Clinical Neuropathology Practice News 3-2012: the ABC in AD – revised and updated guideline for the neuropathologic assessment of Alzheimer’s disease
【2h】

Clinical Neuropathology Practice News 3-2012: the ABC in AD – revised and updated guideline for the neuropathologic assessment of Alzheimer’s disease

机译:临床神经病理学实践新闻3-2012:AD中的 ABC-修订和更新的阿尔茨海默氏病神经病理学评估指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The two major approaches for the neuropathological assessment of Alzheimer’s disease (AD) related pathology have been based on the assessment of neuritic plaques (CERAD) and neurofibrillary pathology (Braak and Braak). In 1997 these two approaches were integrated in the criteria and recommendations of the National Institute on Aging and the Reagan Institute Working group. Recently a new guideline has been published by the National Institute on Aging-Alzheimer’s Association. This new guideline recognizes the existence of a pre-clinical stage of AD as part of continuous neuropathological changes in the background of the disease process, and it fosters the assessment of amyloid-b phases in addition to neurofibrillary degeneration and neuritic plaques following an “ABC” score. Further, it suggests protocols for the neuropathological assessment of additional/concomitant neurodegenerative and vascular pathologies. Altogether, the new guideline responds to the need for an update of the existing “1997 criteria” for AD. Continued studies will have to assess the added value of the new approach and the influence of interlaboratory and/or methodological differences on the implementation of these new recommendations.
机译:阿尔茨海默氏病(AD)相关病理的神经病理学评估的两种主要方法是基于神经斑块(CERAD)和神经原纤维病理学(Braak和Braak)的评估。 1997年,这两种方法被纳入了国家老龄研究所和里根研究所工作组的标准和建议中。最近,美国老年痴呆症协会协会发布了新的指南。这项新指南认识到AD的临床前阶段已作为疾病过程背景中持续的神经病理学变化的一部分,并且除了对“ ABC”后的神经原纤维变性和神经斑块之外,还促进了对淀粉样蛋白b期的评估。 “ 得分了。此外,它提出了用于附加/伴随的神经退行性和血管病理的神经病理学评估的方案。总体而言,新指南满足了对AD的现有“ 1997年标准”进行更新的需求。继续进行的研究将必须评估新方法的附加价值以及实验室间和/或方法学差异对这些新建议的实施的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号